文献速递淋巴瘤

MELK通过位点特异性磷酸化介导结外NK/T细胞淋巴瘤中EZH2的稳定性

MELK mediates the stability of EZH2 through site-specific phosphorylation in extranodal natural killer/T-cell lymphoma.
PubMed 文献 · Blood · 2019-01-01

本研究探讨结外NK/T细胞淋巴瘤(NKTL)中EZH2蛋白周转机制,发现MELK激酶通过磷酸化EZH2 S220并减少K222泛素化来稳定EZH2。MELK在NKTL中上调且与EZH2蛋白表达相关,USP36是去泛素化EZH2 K222的酶。MELK过表达导致硼替佐米敏感性降低,靶向MELK可能成为改善硼替佐米反应不佳患者的新策略。

要点

  • MELK通过磷酸化EZH2 S220并抑制K222泛素化来稳定EZH2蛋白。
  • MELK在NKTL中表达上调,且与EZH2蛋白表达呈正相关。
  • MELK过表达降低NKTL对硼替佐米的敏感性,靶向MELK或可克服耐药。

核心结论

  • MELK和USP36在介导NKTL中EZH2稳定性方面发挥重要作用。
  • 靶向MELK调节EZH2泛素化状态可能是硼替佐米反应不佳NKTL患者的新治疗策略。

研究设计与样本

  • 基础实验研究,使用定量质谱分析、化学和遗传抑制MELK、组织芯片来自NKTL患者。

主要发现

  • 定量质谱显示MELK介导EZH2 S220磷酸化增加,同时伴随EZH2 K222泛素化丢失。
  • 化学和遗传抑制MELK导致EZH2蛋白泛素化和不稳定。
  • MELK在NKTL中上调,其表达与EZH2蛋白表达相关(组织芯片来自NKTL患者)。
  • FOXM1不参与介导EZH2泛素化。
  • USP36被鉴定为在K222位点去泛素化EZH2的去泛素化酶。

临床怎么用

  • 调节EZH2泛素化状态可能作为硼替佐米反应不佳NKTL患者的治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Oncogenic EZH2 is overexpressed and extensively involved in the pathophysiology of different cancers including extranodal natural killer/T-cell lymphoma (NKTL). However, the mechanisms regarding EZH2 upregulation is poorly understood, and it still remains untargetable in NKTL. In this study, we examine EZH2 protein turnover in NKTL and identify MELK kinase as a regulator of EZH2 ubiquitination and turnover. Using quantitative mass spectrometry analysis, we observed a MELK-mediated increase of EZH2 S220 phosphorylation along with a concomitant loss of EZH2 K222 ubiquitination, suggesting a phosphorylation-dependent regulation of EZH2 ubiquitination. MELK inhibition through both chemical and genetic means led to ubiquitination and destabilization of EZH2 protein. Importantly, we determine that MELK is upregulated in NKTL, and its expression correlates with EZH2 protein expression as determined by tissue microarray derived from NKTL patients. FOXM1, which connected MELK to EZH2 signaling in glioma, was not involved in mediating EZH2 ubiquitination. Furthermore, we identify USP36 as the deubiquitinating enzyme that deubiquitinates EZH2 at K222. These findings uncover an important role of MELK and USP36 in mediating EZH2 stability in NKTL. Moreover, MELK overexpression led to decreased sensitivity to bortezomib treatment in NKTL based on deprivation of EZH2 ubiquitination. Therefore, modulation of EZH2 ubiquitination status by targeting MELK may be a new therapeutic strategy for NKTL patients with poor bortezomib response.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Li B, Yan J, Phyu T, et al. MELK mediates the stability of EZH2 through site-specific phosphorylation in extranodal natural killer/T-cell lymphoma. Blood. 2019. PMID: 31434700. doi:10.1182/blood.2019000381

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。